A randomised, two-arm (1:1 ratio), double blind, placebo controlled phase III trial to assess the efficacy, safety, cost and cost-effectiveness of Rituximab in treating de novo or... oleh Lisa C Willcocks, Wendi Qian, Ruzaika Cader, Katrina Gatley, Hira Siddiqui, Endurance Tabebisong, Karlena Champion, Andreas Kronbichler, Liz Lightstone, David Jayne, Edward Wilson, Megan Griffith